文献速递造血干细胞移植与细胞治疗

基于移植后环磷酰胺对比基于抗胸腺细胞球蛋白的HLA错配无关供者移植后改善的无GVHD无复发生存

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant.
PubMed 文献 · Blood Adv · 2022-01-01

该研究比较了128例HLA错配无关供者造血干细胞移植受者中,基于他克莫司/甲氨蝶呤/抗胸腺细胞球蛋白(ATG组,n=46)与基于移植后环磷酰胺(PTCy)、霉酚酸酯和他克莫司或西罗莫司(PTCy组,n=82)预防方案的1年无GVHD无复发生存(GRFS)。PTCy组1年GRFS为54%,ATG组为16%(P<.001),多变量校正风险比为0.34(95%CI:0.21-0.55;P<.001),PTCy组总生存也更优。

要点

  • PTCy组1年GRFS为54%(95%CI:44%-66%),ATG组为16%(95%CI:8%-31%),P<.001。
  • 多变量校正后PTCy组GRFS风险比为0.34(95%CI:0.21-0.55;P<.001)。
  • PTCy组1年总生存为75%(95%CI:66%-85%),ATG组为45%(95%CI:32%-62%),P<.001。

核心结论

  • 基于PTCy的预防方案在HLA错配无关供者移植受者中获得了更优的GRFS和总生存。

研究设计与样本

  • 比较128例接受HLA错配无关供者造血干细胞移植受者的1年GRFS,ATG组46例,PTCy组82例。
  • 纳入HLA-A、HLA-B、HLA-C和HLA-DRB1中至少1个位点错配的HLA错配无关供者移植患者。
  • ATG组预防方案为他克莫司/甲氨蝶呤/抗胸腺细胞球蛋白;PTCy组为移植后环磷酰胺、霉酚酸酯和他克莫司或西罗莫司。

主要发现

  • 1年GRFS在ATG组为16%(95%CI:8%-31%),在PTCy组为54%(95%CI:44%-66%),P<.001。
  • 使用PTCy的GRFS多变量校正风险比为0.34(95%CI:0.21-0.55;P<.001)。
  • 1年总生存ATG组为45%(95%CI:32%-62%),PTCy组为75%(95%CI:66%-85%),P<.001。
  • 复发发生率两组相似。
  • 1年非复发死亡率ATG组为38%(95%CI:23%-52%),PTCy组为16%(95%CI:9%-25%),P<.001。

关键数值与推荐

  • PTCy组更多患者接受骨髓移植物(50% vs 26%;P=.01)。
  • PTCy组更多患者接受>1个位点HLA错配的移植物(30.5% vs 2.2%;P=.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A common method to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT) from an HLA-mismatched unrelated donor (MMUD) is tacrolimus, methotrexate, and antithymocyte globulin (ATG). The use of posttransplant cyclophosphamide (PTCy) showed promise in a prospective trial for MMUD HCT. We compared 1-year graft-versus-host disease-free, relapse-free survival (GRFS) in 128 recipients of prophylaxis based on tacrolimus/methotrexate/ATG (ATG group, n = 46) vs PTCy, mycophenolate mofetil, and tacrolimus or sirolimus (PTCy group, n = 82) after MMUD HCT. Patients receiving HCT from a MMUD mismatched at ≥1 locus among HLA-A, HLA-B, HLA-C, and HLA-DRB1 were included. The 2 groups were well matched for HCT indication, high-risk disease, and HCT comorbidity index, whereas more patients on PTCy received bone marrow (50% vs 26%; P = .01) and >1 locus HLA-mismatched (30.5% vs 2.2%; P = .001) grafts. The 1-year GRFS was 16% (95% confidence interval (CI): 8%-31%) vs 54% (95% CI: 44%-66%; P < .001) in the ATG and PTCy groups, respectively. The multivariable adjusted hazard ratio for GRFS was 0.34 (95% CI: 0.21-0.55; P < .001) with the use of PTCy. The 1-year overall survival in the ATG group was 45% (95% CI: 32%-62%) vs 75% (95% CI: 66%-85%) in the PTCy group (P < .001). Relapse incidence was similar. One-year nonrelapse mortality was greater after ATG-based prophylaxis: 38% (95% CI: 23%-52%) vs 16% (95 CI: 9%-25%), P < .001. In summary, PTCy-based prophylaxis resulted in superior GRFS and overall survival in recipients of MMUD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jimenez Jimenez A, Komanduri K, Brown S, et al. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Adv. 2022. PMID: 35793451. doi:10.1182/bloodadvances.2022007596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。